Meningioma Prognostic Tool Based on Correlation of Histopathological Grading and Immunohistochemistry

Mahak Shafat1, Nayil Khursheed1, Nazia Walvir1

  • 1Department of Pathology and Neurosurgery, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.

Oman Medical Journal
|July 26, 2024
PubMed
Abstract

Insights

Estrogen receptor (ER), progesterone receptor (PR), and Ki-67/MIB-1 levels vary significantly across meningioma grades. PR expression is a positive prognostic indicator, while Ki-67/MIB-1 correlates with tumor grade and recurrence risk.

Area of Science:

  • Neuro-oncology
  • Pathology
  • Molecular Biology

Background:

  • Meningiomas are graded I-III, but grade alone doesn't predict patient outcomes.
  • Estrogen receptor (ER), progesterone receptor (PR), and Ki-67/MIB-1 are key markers in meningioma research.
  • Understanding these markers' expression across grades is crucial for prognosis.

Purpose of the Study:

  • To evaluate ER, PR, and Ki-67/MIB-1 status in different grades of meningioma.
  • To correlate these markers with meningioma grade and potential patient outcomes.

Main Methods:

  • Retrospective and prospective analysis of 276 meningioma cases over 10 years.
  • Re-grading of tumors using WHO 2021 criteria.
  • Immunohistochemical analysis for ER, PR, and Ki-67/MIB-1 in all grades.

Main Results:

  • ER positivity decreased from grade 1 (26.0%) to grade 3 (0.0%).
  • PR positivity decreased from grade 1 (70.0%) to grade 2 (5.8%), but was similar in grade 3 (18.0%).
  • Ki-67/MIB-1 labeling index significantly increased with tumor grade (Grade 1: 2.1, Grade 2: 6.3, Grade 3: 13.4).

Conclusions:

  • Ki-67/MIB-1 is a valuable marker for assessing meningioma grade and recurrence risk.
  • PR expression is a positive prognostic indicator and correlates with histological grade.
  • Combining PR status and MIB-1 LI aids in predicting meningioma behavior and recurrence probability, especially in challenging cases.

Related Concept Videos